News
We send the latest information from SMC Laboratories.
Poster presentation selected for the EASL Congress 2024, data on STAM mice in the field of Immune-oncology
We are pleased to announce that the latest pathology and pathogenesis data in the field of immuno-oncology on STAM™-HCC/IO⁺ mouse will be presented in a poster at the EASL Congress 2024 in Milan, Italy, June 5-8, 2024. The STAM™-HCC/IO⁺ mouse is the first preclinical model in the field of immuno-oncology for the development of new…
SMC will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology
We are pleased to announce that SMC Laboratories will be exhibiting at The 110th General Meeting of the Japanese Society of Gastroenterology from May 9th (Thu) to 11th (Sat). In the Exhibition section, we will introduce our drug efficacy evaluation study services using our original MASH (NASH)-hepatocarcinoma model, STAM™ mouse, as well as other…
【Breaking News!】 First MASH treatment approved by FDA
On March 14th, The United States Food and Drug Administration (FDA) announced their approval of Rezdiffra (resmetirom), developed by Madrigal Pharmaceuticals, as the first treatment for MASH. ► FDA NEWS RELEASE FDA approved first MASH treatment It took more than 15 years for Rezdiffra to be approved for the treatment of MASH,…
What is the best non-clinical liver cancer model with 100% cancer incidence rate and suitable for liver cancer assessment?
If you are considering a drug evaluation study for liver cancer using a mouse model, our STAM™-HCC/IO⁺ model best replicates the pathology and characteristics seen in human patients with liver cancer, which allows for the optimal evaluation of your compound's efficacy. In addition to molecular targeted drugs such as lenvatinib and sorafenib, immune checkpoint…
The [optimal disease model] that maximizes your research outputs.
The bleomycin-induced pulmonary fibrosis mouse model is commonly used to replicate the pathogenesis of IPF in humans. If you are considering using a mouse model of pulmonary fibrosis for drug evaluation studies, then using a suitable study design allows you to best evaluate the efficacy of your compound. As mentioned in a previous news,…
【Case Study】Why do disease model mice change the outcomes?
If you are considering using a lung fibrosis model in a drug efficacy study, you can maximize the efficacy of your compound by using a disease induction model that is appropriate for your evaluation, rather than using a standard pathological model. Today, we will provide a clear overview of the disease induction periods in…
Introduction of [Pathway MAP of MASH compounds] to accelerate your research
When conducting non-clinical research, it is important to choose an appropriate mouse model that reproduces human pathology and also allows your compound to be evaluated. In this post you will find the appropriate model mouse for your compound and the results. As a pioneer in the field of MASH/NASH, we have conducted more…
Preclinical COPD study with positive controls, Roflumilast
Today, we share an update regarding new preclinical service. It is now possible to use a positive control (Roflumilast) in a drug efficacy evaluation study using PPE-induced COPD model. The drug used as a positive control is roflumilast, a PDE-4 inhibitor. Mean linear intercept by histological analysis of the lungs, the primary endpoint…
Introduction of Chronic Kidney Disease Mice Models
I am writing you today to share some information on our chronic kidney disease (CKD) models. CKD is a condition that is characterized by abnormalities in the structure or function of the kidneys. It is a global public health problem and causes a rising incidence and prevalence of kidney failure with poor outcomes. However,…
Cholangiocarcinoma and Primary sclerosing cholangitis
On February 15, World Cholangiocarcinoma Day! Today we would like to introduce cholangiocarcinoma (CCA, bile duct cancer) and its risk factor, primary sclerosing cholangitis (PSC). CCA is the second most common liver cancer after hepatocellular carcinoma, and its incidence appears to be increasing worldwide (Banales JM et al., Nat Rev Gastroenterol Hepatol. 2020)….